From development to cancer: Lessons from the kidney to uncover new therapeutic targets

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3609-3617

  Dormoy, Valérian ^a   Jacqmin, Didier ^b   Lang, Hervé ^b   Massfelder, Thierry ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b New Hospital of Strasbourg   (France)

Author keywords

Developmental markers; Kidney; Renal cell carcinoma; Review; Signaling pathways; Therapeutic targets; VHL tumor suppressor

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; HOMEOBOX PROTEIN LIM 1; HOMEODOMAIN PROTEIN; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR PAX2; UNCLASSIFIED DRUG; WNT PROTEIN; WT1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; DRUG SAFETY; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; KIDNEY DEVELOPMENT; NEPHROGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; CARCINOMA, RENAL CELL; CELL TRANSFORMATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; KIDNEY; KIDNEY NEOPLASMS; LIM-HOMEODOMAIN PROTEINS; MOLECULAR TARGETED THERAPY; PAX2 TRANSCRIPTION FACTOR; RECEPTORS, NOTCH; WNT PROTEINS; WT1 PROTEINS;

EID: 84867006576     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. McDermott DF: Immunotherapy of metastatic renal cell carcinoma. Cancer 115: 2298-2305, 2009.
2. Motzer RJ and Russo P: Systemic therapy for renal cell carcinoma. J Urol 163: 408-417, 2000. (Pubitemid 30060482)
3. Ljungberg B, Campbell SC, Choi HY, Jacqmin, D, Lee, JE, Weikert S and Kiemeney LA: The epidemiology of renal cell carcinoma. Eur Urol 60: 615-621, 2011.
4. Clark PE: The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int 76: 939-45, 2009.
5. Kaelin WG: Von Hippel-Lindau disease. Annu Rev Pathol 2: 145-173, 2007.
6. Sourbier C and Massfelder T: Parathyroid hormone-related protein in human renal cell carcinoma. Cancer Lett 240: 170-182, 2006. (Pubitemid 44093817)
7. Escudier B, Eisen T, Stadler WM Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C and Bukowski RM: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318, 2009.
8. Clark PE. Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol 17: 331-336, 2007. (Pubitemid 47344620)
9. O'Mahony FC, Faratian D, Varley J, Nanda J, Theodoulou M, Riddick AC, Harrison DJ and Stewart GD: The use of automated quantitative analysis to evaluate epithelial-to-mesenchymal transition associated proteins in clear cell renal cell carcinoma. PLoS One 7: e31557, 2012.
10. Raimondo F, Salemi C, Chinello C, Fumagalli D, Morosi L, Rocco F, Ferrero S, Perego R, Bianchi C, Sarto C, Pitto M, Brambilla P and Magni F: Proteomic analysis in clear cell renal cell carcinoma: identification of differentially expressed protein by 2-D DIGE. Mol Biosyst 8: 1040-1051, 2012.
11. Audenet F, Yates DR, Cancel-Tassin G, Cussenot O and Roupret M: Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int 109: 1864-1870, 2012.
12. Ly JP, Onay T and Quaggin SE: Mouse models to study kidney development, function and disease. Curr Opin Nephrol Hypertens 20: 382-390, 2011.
13. Dressler GR: Advances in early kidney specification, development and patterning. Development 136: 3863-3874, 2009.
14. Michos O: Kidney development: from ureteric bud formation to branching morphogenesis. Curr Opin Genet Dev 19: 484-490, 2009.
15. Reidy KJ and Rosenblum ND: Cell and molecular biology of kidney development. Semin Nephrol 29: 321-337, 2009.
16. Kobayashi A, Kwan KM, Carroll TJ, McMahon AP, Mendelsohn CL and Behringer RR: Distinct and sequential tissue-specific activities of the LIM-class homeobox gene Lim1 for tubular morphogenesis during kidney development. Development 132: 2809-2823, 2005. (Pubitemid 40932870)
17. Drews C, Senkel S and Ryffel GU: The nephrogenic potential of the transcription factors osr1, osr2, hnf1b, lhx1 and pax8 assessed in Xenopus animal caps. BMC Dev Biol 11: 5, 2011.
18. Cirio MC, Hui Z, Haldin CE, Cosentino CC, Stuckenholz C, Chen X, Hong SK, Dawid IB and Hukriede NA: Lhx1 is required for specification of the renal progenitor cell field. PLoS One 6 : e18858, 2011.
19. Venegas-Ferrin M, Sudou N, Taira M and del Pino EM: Comparison of Lim1 expression in embryos of frogs with different modes of reproduction. Int J Dev Biol 54: 195-202, 2010.
20. Holland PW, Booth HA and Bruford EA: Classification and nomenclature of all human homeobox genes. BMC Biol 5: 47, 2007.
21. Shawlot W and Behringer RR: Requirement for Lim1 in head-organizer function. Nature 374: 425-430, 1995.
22. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R: WT-1 is required for early kidney development. Cell 74: 679-691, 1993. (Pubitemid 23259748)
23. Md Zin R, Murch A and Charles A: Pathology, genetics and cytogenetics of Wilms' tumour. Pathology 43: 302-312, 2011.
24. Pulkkinen K, Murugan S and Vainio S: Wnt signaling in kidney development and disease. Organogenesis 4: 55-59, 2008. (Pubitemid 351881300)
25. McCright B: Notch signaling in kidney development. Curr Opin Nephrol Hypertens 12: 5-10, 2003.
26. Sourbier C, Lindner V, Lang H, Agouni A, Schordan E, Danilin S, Rothhut S, Jacqmin D, Helwig JJ, and Massfelder T: The phosphoinositide 3-kinase/AKT pathway: a new target in human renal cell carcinoma therapy. Cancer Res 66: 5130-5142, 2006. (Pubitemid 43844935)
27. Huang D, Ding Y, Luo WM, Bender S, Qian CN, Kort E, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH and Teh BT: Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res 68: 81-88, 2008. (Pubitemid 351380108)
28. Sourbier C, Danilin S, Lindner V, Steger J, Rothhut S, Meyer N, Jacqmin D, Helwig JJ, Lang H and Massfelder T: Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res 67: 11668-11676, 2007.
29. Gill PS and Rosenblum ND: Control of murine kidney development by sonic hedgehog and its GLI effectors. Cell Cycle 5: 1426-1430, 2006. (Pubitemid 44153652)
30. Gnarra JR and Dressler GR. Expression of PAX2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res 55: 4092-4098, 1995.
31. Daniel L, Lechevallier E, Giorgi R, Sichez H, Zattara-Cannoni H, Figarella-Branger D and Coulange C: PAX2 expression in adult renal tumors. Hum Pathol 32: 282-287, 2001. (Pubitemid 32246801)
32. Hueber PA, Waters P, Clark P, Eccles M and Goodyer P: PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney Int 69: 1139-1145, 2006.
33. Doberstein K, Pfeilschifter J and Gutwein P: The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma. Carcinogenesis 32: 1713-1723, 2011.
34. Fonsato V, Buttiglieri S, Deregibus MC, Puntorieri V, Bussolati B and Camussi G: Expression of PAX2 in human renal tumor-derived endothelial cells sustains apoptosis resistance and angiogenesis. Am J Pathol 168: 706-713, 2006. (Pubitemid 43271166)
35. Luu VD, Boysen G, Struckmann K, Casagrande S, von Teichman A, Wild PJ, Sulser T, Schraml P and Moch H: Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clin Cancer Res 15: 3297-3304, 2009.
36. Hueber PA, Iglesias D, Chu LL, Eccles M and Goodyer P: In vivo validation of PAX2 as a target for renal cancer therapy. Cancer Lett 265: 148-155, 2008.
37. Gokden N, Kemp SA and Gokden M: The utility of PAX2 as an immunohistochemical marker for renal cell carcinoma in cytopathology. Diagn Cytopathol 36: 473-477, 2008. (Pubitemid 351897373)
38. Ozcan A, Zhai Q, Javed R, Shen SS, Coffey D, Krishnan B, Truong LD: PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin. Arch Pathol Lab Med 134: 1121-1129, 2010.
39. Sharma SG, Gokden M, McKenney JK, Phan DC, Cox RM, Kelly T and Gokden N: The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features. Appl Immunohistochem Mol Morphol 18: 494-498, 2010.
40. Sangoi AR, Karamchandani J, Kim J, Pai RK and McKenney JK: The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: A review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10. Adv Anat Pathol 17: 377-393, 2010.
41. Ozcan A, Zhai J, Hamilton C, Shen SS, Ro JY, Krishnan B, Truong LD: PAX-2 in the diagnosis of primary renal tumors: immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin. Am J Clin Pathol 131: 393-404, 2009.
42. Gokden N, Gokden M, Phan DC and McKenney JK: The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol 32: 1462-1467, 2008.
43. Knoepp SM, Kunju LP and Roh MH: Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology. Diagn Cytopathol, 2010 [Epub ahead of print].
44. Kawakami K, Hirata H, Yamamura S, Kikuno N, Saini S, Majid S, Tanaka Y, Kawamoto K, Enokida H, Nakagawa M and Dahiya R: Functional significance of WNT inhibitory factor-1 gene in kidney cancer. Cancer Res 69: 8603-8610, 2009.
45. Banumathy G and Cairns P: Signaling pathways in renal cell carcinoma. Cancer Biol Ther 10: 658-664, 2010.
46. Saini S, Majid S and Dahiya R: The complex roles of WNT antagonists in RCC. Nat Rev Urol 8: 690-699, 2011.
47. Ueno K, Hirata H, Majid S, Chen Y, Zaman MS, Tabatabai ZL, Hinoda Y, and Dahiya R: WNT antagonist DICKKOPF-3 (DKK-3) induces apoptosis in human renal cell carcinoma. Mol Carcinog 50: 449-457, 2011.
48. Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, Ueno K, Yamamura S, Zaman MS, Khatri G, Chen Y, Saini S, Majid S, Deng G, Ishii N and Dahiya R: WNT antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer 128: 1793-1803, 2010.
49. Campbell CE, Kuriyan NP, Rackley RR, Caulfield MJ, Tubbs R, Finke J and Williams BR: Constitutive expression of the Wilms' tumor suppressor gene (WT1) in renal cell carcinoma. Int J Cancer 78: 182-188, 1998. (Pubitemid 28443175)
50. Sitaram RT, Degerman S, Ljungberg B, Andersson E, Oji Y, Sugiyama H, Roos G and Li A: Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. Br J Cancer 103: 1255-1262, 2010.
51. Kreidberg JA and Hartwig S: Wilms' tumor-1: A riddle wrapped in a mystery, inside a kidney. Kidney Int 74: 411-412, 2008.
52. Sun S, Du R, Gao J, Ning X, Xie H, Lin X, Liu J, Fan D: Expression and clinical significance of Notch receptors in human renal cell carcinoma. Pathology 41: 335-341, 2009.
53. Aparicio LM, Villaamil VM, Gallego GA, Cainzos IS, Campelo RG, Rubira LV, Estevez SV, Mateos LL, Perez JL, Vazquez MR, Calvo OF and Bolos MV: Expression of Notch1 to -4 and their ligands in renal cell carcinoma: a tissue microarray study. Cancer Genomics Proteomics 8: 93-101, 2011.
54. Sjolund J, Johansson M, Manna S, Norin C, Pietras A, Beckman S, Nilsson E, Ljungberg B and Axelson H: Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 118: 217-228, 2008.
55. Katoh Y and Katoh M: Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 9: 873-886, 2009.
56. Stanton BZ and Peng LF: Small-molecule modulators of the sonic hedgehog signaling pathway. Mol Biosyst 6: 44-54, 2009.
57. Dormoy V, Danilin S, Lindner V, Thomas L, Rothhut S, Coquard C, Helwig JJ, Jacqmin D, Lang H and Massfelder T: The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth. Mol Cancer 8: 123, 2009.
58. Varis A, Wolf M, Monni O, Vakkari ML, Kokkola A, Moskaluk C, Frierson H Jr., Powell SM, Knuutila S, Kallioniemi A, El-Rifai W: Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res 62: 2625-2629, 2002. (Pubitemid 34462744)
59. Dormoy V, Beraud C, Lindner V, Thomas L, Coquard C, Barthelmebs M, Jacqmin D, Lang H and Massfelder T: LIM-class homeobox gene LIM1, a novel oncogene in human renal cell carcinoma. Oncogene 30: 1753-1763, 2011.
60. Guertl B, Senanayake U, Nusshold E, Leuschner I, Mannweiler S, Ebner B and Hoefler G: LIM1, an embryonal transcription factor, is absent in multicystic renal dysplasia, but reactivated in nephroblastomas. Pathobiology 78: 210-219, 2011.
61. Muratovska A, Zhou C, He S, Goodyer P and Eccles MR: Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22: 7989-7997, 2003. (Pubitemid 37179944)
62. Khoubehi B, Kessling AM, Adshead JM, Smith GL, Smith RD and Ogden CW: Expression of the developmental and oncogenic PAX2 gene in human prostate cancer. J Urol 165: 2115-2120, 2001.
63. Gibson W, Green A, Bullard RS, Eaddy AC and Donald CD: Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status. Cancer Lett 248: 251-261, 2007. (Pubitemid 46330557)
64. Bose SK, Gibson W, Bullard RS and Donald CD: PAX2 oncogene negatively regulates the expression of the host defense peptide human beta defensin-1 in prostate cancer. Mol Immunol 46: 1140-1148, 2009.
65. Beauchemin D, Lacombe C and Van Themsche C: PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype. Mol Cancer 10: 148, 2011.
66. Silberstein GB, Dressler GR and Van Horn K: Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth. Oncogene 21: 1009-1016, 2002. (Pubitemid 34174513)
67. Lee SB, Doberstein K, Baumgarten P, Wieland A, Ungerer C, Burger C, Hardt K, Boehncke WH, Pfeilschifter J, Mihic-Probst D, Mittelbronn M and Gutwein P: PAX2 regulates ADAM10 expression and mediates anchorage-independent cell growth of melanoma cells. PLoS One 6: e22312, 2011.
68. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM and Wong KK: PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 22: 1243-1250, 2009.
69. Roh MH, Yassin Y, Miron A, Mehra KK, Mehrad M, Monte NM, Mutter GL, Nucci MR, Ning G, McKeon FD, Hirsch MS, Wa X and Crum CP: High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol 23: 1316-1324, 2010.
70. Manetti F: Recent findings confirm lim domain kinases as emerging target Candidates for cancer therapy. Curr Cancer Drug Targets 12: 543-560, 2012.
71. Rosenfeld C, Cheever MA and Gaiger A: WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: Therapeutic potential of WT1-targeted therapies. Leukemia 17: 1301-1312, 2003. (Pubitemid 36857337)
72. Sugiyama H: WT1 (Wilms' tumor gene 1): Biology and cancer immunotherapy. Jpn J Clin Oncol 40: 377-387, 2010.
73. Cilloni D and Saglio G: WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 112: 79-84, 2004. (Pubitemid 38716252)
74. Saglio G, Carturan S, Grillo S, Capella S, Arruga F, Defilippi I, Rosso V, Rauco M, Marina Liberati A and Cilloni D: WT1 overexpression: a clinically useful marker in acute and chronic myeloid leukemias. Hematology 10(Suppl 1): 76-78, 2005. (Pubitemid 41825696)
75. Oka Y, Tsuboi A, Oji Y, Kawase I and Sugiyama H: WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20: 211-220, 2008.
76. Oka Y, Tsuboi A, Fujiki F, Li Z, Nakajima H, Hosen N, Shirakata T, Nishida S, Oji Y, Kawase I and Sugiyama H: WT1 peptide vaccine as a paradigm for 'cancer antigen-derived peptide'-based immunotherapy for malignancies: successful induction of anticancer effect by vaccination with a single kind of WT1 peptide. Anticancer Agents Med Chem 9: 787-797, 2009.
77. Sarmento LM and Barata JT: Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises. Expert Rev Anticancer Ther 11: 1403-1415, 2011.
78. Miyamoto S and Rosenberg DW: Role of Notch signaling in colon homeostasis and carcinogenesis. Cancer Sci 102: 1938-1942, 2011.
79. Sethi N and Kang Y: Notch signalling in cancer progression and bone metastasis. Br J Cancer 105: 1805-1810, 2011.
80. Wang Z, Ahmad A, Li Y, Azmi AS, Miele L and Sarkar FH: Targeting Notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res 31: 1105-13, 2011.
81. Guo S, Liu M and Gonzalez-Perez RR: Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta 1815: 197-213, 2011.
82. Takebe N, Harris PJ, Warren RQ and Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8: 97-106, 2010.
83. Curtin JC and Lorenzi MV: Drug discovery approaches to target WNT signaling in cancer stem cells. Oncotarget 1: 563-577, 2011.
84. de Sousa EM, Vermeulen L, Richel D and Medema JP: Targeting WNT signaling in colon cancer stem cells. Clin Cancer Res 17: 647-653, 2010.
85. Lucero OM, Dawson DW, Moon RT and Chien AJ: A reevaluation of the 'oncogenic' nature of WNT/beta-catenin signaling in melanoma and other cancers. Curr Oncol Rep 12: 314-318, 2010.
86. Marini KD, Payne BJ, Watkins DN and Martelotto LG: Mechanisms of hedgehog signalling in cancer. Growth Factors 29: 221-234, 2011.
87. Onishi H and Katano M: Hedgehog signaling pathway as a therapeutic target in various types of cancer. Cancer Sci 102: 1756-1760, 2011.
88. Gould A and Missailidis S: Targeting the hedgehog pathway: the development of cyclopamine and the development of anticancer drugs targeting the hedgehog pathway. Mini Rev Med Chem 11: 200-213, 2011.
89. Barakat MT, Humke EW and Scott MP: Learning from Jekyll to control Hyde: Hedgehog signaling in development and cancer. Trends Mol Med 16: 337-348, 2010.
90. Nehme R and Mus-Veteau I: Proteins of the hedgehog signaling pathway as therapeutic targets against cancer. Expert Rev Proteomics 7 : 601-612, 2010.